Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD

Blood eosinophil count in chronic obstructive pulmonary disease (COPD) is associated with higher exacerbation rate and favourable response to corticosteroids; however, frequent exacerbations and use of inhaled corticosteroids could elevate pneumonia risk. We tested the hypothesis that high blood eosinophil counts are associated with high risk of pneumonia in individuals with severe COPD from the general population. We included 7180 individuals with COPD from the Copenhagen General Population Study, including 643 with forced expiratory volume in 1 s (FEV1) <50% predicted between 2003 and 2011. All primary discharge diagnoses of pneumonia during follow-up were recorded. Among individuals with COPD and FEV1 <50% pred, the multivariable adjusted incidence rate ratio was 2.17 (95% CI 1.31–3.58) for pneumonia comparing individuals with blood eosinophil counts ≥0.34×109 cells·L−1 versus <0.34×109 cells·L−1. In individuals with clinical COPD, defined by recent exacerbation, ≥10 pack-years of smoking and FEV1 <70% pred, the corresponding risk was 4.52 (2.11–9.72). Risk of pneumonia did not differ by blood eosinophil count in individuals with COPD and FEV1 ≥50% pred. In individuals with COPD and FEV1 <50% pred, blood eosinophil count ≥0.34×109 cells·L−1 was associated with high risk of hospitalisation due to pneumonia. Eosinophilic COPD with severely impaired lung function is associated with high risk of pneumonia hospitalisations http://ow.ly/Tyl130jsi1D

[1]  M. Cosio,et al.  Blood Eosinophilia Neither Reflects Tissue Eosinophils nor Worsens Clinical Outcomes in Chronic Obstructive Pulmonary Disease. , 2017, American journal of respiratory and critical care medicine.

[2]  J. Soriano,et al.  Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD , 2017, European Respiratory Journal.

[3]  E. Wouters,et al.  Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts. , 2017, American journal of respiratory and critical care medicine.

[4]  J. Wedzicha,et al.  Blood and sputum eosinophils in COPD; relationship with bacterial load , 2017, Respiratory Research.

[5]  J. Wedzicha,et al.  Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial , 2017, American journal of respiratory and critical care medicine.

[6]  B. Nordestgaard,et al.  Association of Blood Eosinophil and Blood Neutrophil Counts with Asthma Exacerbations in the Copenhagen General Population Study. , 2017, Clinical chemistry.

[7]  A. Vanasse,et al.  Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions , 2017, Chest.

[8]  I. Pavord,et al.  Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. , 2016, The Lancet. Respiratory medicine.

[9]  Sally J. Singh,et al.  Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. , 2016, Chest.

[10]  P. Jones,et al.  Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD , 2016, International journal of chronic obstructive pulmonary disease.

[11]  J. Wedzicha,et al.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.

[12]  B. Nordestgaard,et al.  Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. , 2016, American journal of respiratory and critical care medicine.

[13]  B. Nordestgaard,et al.  Blood Eosinophils and Exacerbations in COPD: the Copenhagen General Population Study. , 2015 .

[14]  I. Pavord,et al.  Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD , 2015, Thorax.

[15]  S. Gungor,et al.  The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia , 2015, International journal of chronic obstructive pulmonary disease.

[16]  J. Wedzicha,et al.  Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[17]  F. Blasi,et al.  Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease , 2015, Thorax.

[18]  B. Nordestgaard,et al.  Characteristics and Prognosis of Never-Smokers and Smokers with Asthma in the Copenhagen General Population Study. A Prospective Cohort Study. , 2015, American journal of respiratory and critical care medicine.

[19]  I. Pavord,et al.  Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. , 2015, The Lancet. Respiratory medicine.

[20]  M. Woodhead,et al.  Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance , 2014, BMJ : British Medical Journal.

[21]  Dave Singh,et al.  Eosinophilic inflammation in COPD: prevalence and clinical characteristics , 2014, European Respiratory Journal.

[22]  B. Nordestgaard,et al.  Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. , 2013, JAMA.

[23]  F. Martinez,et al.  Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.

[24]  B. Nordestgaard,et al.  Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[25]  John Steer,et al.  The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease , 2012, Thorax.

[26]  J. Wedzicha,et al.  The natural history of community-acquired pneumonia in COPD patients: a population database analysis. , 2012, Respiratory medicine.

[27]  Christopher E Brightling,et al.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.

[28]  S. Cole,et al.  Overadjustment Bias and Unnecessary Adjustment in Epidemiologic Studies , 2009, Epidemiology.

[29]  P. Jones,et al.  Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.

[30]  David J Murphy,et al.  Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2008, JAMA.

[31]  A. Torres,et al.  New evidence of risk factors for community-acquired pneumonia: a population-based study , 2008, European Respiratory Journal.

[32]  Susanna Navarro,et al.  Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysaccharides and peptidoglycans. , 2008, Biochemistry.

[33]  T. Lasserson,et al.  Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.

[34]  F. Maltais,et al.  Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment , 2006, European Respiratory Journal.

[35]  I. Jónsdóttir,et al.  Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local TH2-like response. , 2005, The Journal of allergy and clinical immunology.

[36]  D. Postma,et al.  Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. , 1999, American journal of respiratory and critical care medicine.

[37]  J. Vestbo,et al.  Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. , 1995, The European respiratory journal.

[38]  C. McCall,et al.  Eosinopenia of acute infection: Production of eosinopenia by chemotactic factors of acute inflammation. , 1980, The Journal of clinical investigation.